Update: Apo-Metformin Extended Release Recall
Apotex Inc. is recalling eight lots of its 500 mg extended release metformin tablets (“APO-Metformin ER”) because they contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) above the acceptable limit. Apotex Inc. has tested all lots of its 500 mg extended release tablets; only the affected lots are being recalled. Impacted patients are to talk to their pharmacists and prescribers prior to stopping their doses.
Please read the Health Canada Alert.
Update: Canagliflozin New Indications
Canagliflozin (Invokana) now has these indications:
Add-on combination in patients with established cardiovascular disease: INVOKANA® is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD).
Patients with Diabetic Nephropathy: INVOKANA® is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of end-stage kidney disease, doubling of serum creatinine, and cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria (>33.9 mg/mmol).
Update: Commercial Drivers on Insulin Can Now Cross Border
The Canadian Council of Motor Transport Administrators (CCMTA) now indicates that an individual with a stable insulin regimen and properly controlled insulin‐treated diabetes is qualified to operate a commerical vehicle when crossing the border into the U.S. Canadian Commercial Motor Vehicle operators treated with insulin are encouraged to contact their licensing jurisdictions to learn how to update their licence to allow them to operate in the United States. Please read the letter to the Canadian Trucking Alliance from the CCMTA.